CVE-2025-53094

ESPAsyncWebServer Vulnerable to CRLF Injection in AsyncWebHeader.cpp

Description

ESPAsyncWebServer is an asynchronous HTTP and WebSocket server library for ESP32, ESP8266, RP2040 and RP2350. In versions up to and including 3.7.8, a CRLF (Carriage Return Line Feed) injection vulnerability exists in the construction and output of HTTP headers within `AsyncWebHeader.cpp`. Unsanitized input allows attackers to inject CR (`\r`) or LF (`\n`) characters into header names or values, leading to arbitrary header or response manipulation. Manipulation of HTTP headers and responses can enable a wide range of attacks, making the severity of this vulnerability high. A fix is available at pull request 211 and is expected to be part of version 3.7.9.

Category

8.7
CVSS
Severity: High
CVSS 4.0 •
EPSS 0.04%
Affected: ESP32Async ESPAsyncWebServer
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2025-53094?
CVE-2025-53094 has been scored as a high severity vulnerability.
How to fix CVE-2025-53094?
To fix CVE-2025-53094, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2025-53094 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2025-53094 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2025-53094?
CVE-2025-53094 affects ESP32Async ESPAsyncWebServer.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.